pigment epithelium


Also found in: Medical.

pigment epithelium

[‚pig·mənt ‚ep·ə′thē·lē·əm]
(histology)
A heavily pigmented layer of epithelial cells interposed between the photoreceptors of the vertebrate retina and their blood supply, the choroid. It forms a barrier regulating the exchange of fluids and substances between the blood and outer layer of the retina; it also plays a number of roles in support of photoreceptor structure and function in vertebrates.
McGraw-Hill Dictionary of Scientific & Technical Terms, 6E, Copyright © 2003 by The McGraw-Hill Companies, Inc.
References in periodicals archive ?
The program and its award are distinct from OpRegen, the Company's clinical-stage cell therapy program which features the sub-retinal delivery of retinal pigment epithelium cells for the treatment of dry-AMD.
The program and its award are distinct from OpRegen, the company's clinical-stage cell therapy programme which features the sub-retinal delivery of retinal pigment epithelium cells for the treatment of dry-AMD.
(NYSE American:BTX) announced that it has dosed its first patient with the Orbit Subretinal Delivery System (Orbit SDS) as well as with a new Thaw-and-Inject formulation of OpRegen , the company's retinal pigment epithelium (RPE) transplant therapy.
These five new products add to the already-existing Tempo Bioscience product line and expand TempoStemBank-iPSC offerings: 1) neurons and glia in the central nervous system; 2) neurons in the peripheral nervous system; 3) keratinocytes and melanocytes in the skin; 4) hepatocytes in the liver; and 5) retinal pigment epithelium cells in the eye.
(NYSE American: BTX) said it will present updated results at an upcoming ophthalmology meeting from a Phase l/2a clinical study of its lead product candidate, OpRegen, a retinal pigment epithelium (RPE) cell transplant therapy in development for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy.
(NYSE American: BTX) said it will present updated results at an upcoming ophthalmology meeting from a Phase 1/2a clinical study of its lead product candidate, OpRegen, a retinal pigment epithelium (RPE) cell transplant therapy in development for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy.
OpRegen is a retinal pigment epithelium cell replacement therapy in Phase 2 development for the treatment of dry-AMD, the leading cause of blindness in the developed world.
BioTime announced that updated results from a Phase I/IIa study of its lead product candidate, OpRegen, a retinal pigment epithelium cell transplant therapy currently in development for the treatment of dry age-related macular degeneration, will be presented at the 2019 Association for Research in Vision and Ophthalmology Annual Meeting, to be held April 28 through May 2, 2019 at the Vancouver Convention Centre in Vancouver, BC, Canada.
Congenital Abnormalities of the Retinal Pigment Epithelium. In: Marmor MF, Wolfenberger TJ, eds.
Thanks to its longer wavelength, ICGA enables better visualization of lesions underlying the retinal pigment epithelium (RPE), even in the presence of blood, exudate, and pigment epithelium detachment (PED).
HCQ is known to cause retinal damage in some patients, binding to and accumulating in the retinal pigment epithelium melanin.
(11) showed that perifoveal retinal ganglion cell-inner plexiform layer (RGC-IPL) thickness decreased in patients who had been taking HCQ for a long time before any functional or structural impairment occurred in retinal pigment epithelium layer and photoreceptors.